{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Embryonal+Neoplasm",
    "query": {
      "condition": "Embryonal Neoplasm"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5109,
    "total_pages": 511,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Embryonal+Neoplasm&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T03:00:22.851Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01222728",
      "title": "Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neoplasms",
        "Nervous System Disease",
        "Vestibular Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 5,
      "start_date": "2010-09-22",
      "completion_date": "2015-06-03",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-07-22T03:00:22.851Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01222728"
    },
    {
      "nct_id": "NCT02482532",
      "title": "Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "tvs-CTL Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gary Doolittle",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 7,
      "start_date": "2016-10-06",
      "completion_date": "2021-09-13",
      "has_results": false,
      "last_update_posted_date": "2022-02-04",
      "last_synced_at": "2026-07-22T03:00:22.851Z",
      "location_count": 1,
      "location_summary": "Fairway, Kansas",
      "locations": [
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02482532"
    },
    {
      "nct_id": "NCT03420963",
      "title": "Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Cutaneous Melanoma",
        "Recurrent Lip and Oral Cavity Carcinoma",
        "Recurrent Malignant Endocrine Neoplasm",
        "Recurrent Malignant Female Reproductive System Neoplasm",
        "Recurrent Malignant Male Reproductive System Neoplasm",
        "Recurrent Malignant Mesothelioma",
        "Recurrent Malignant Neoplasm of Multiple Primary Sites",
        "Recurrent Malignant Oral Neoplasm",
        "Recurrent Malignant Pharyngeal Neoplasm",
        "Recurrent Malignant Skin Neoplasm",
        "Recurrent Malignant Soft Tissue Neoplasm",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Malignant Thyroid Gland Neoplasm",
        "Recurrent Malignant Urinary System Neoplasm",
        "Refractory Cutaneous Melanoma",
        "Refractory Malignant Bone Neoplasm",
        "Refractory Malignant Endocrine Neoplasm",
        "Refractory Malignant Female Reproductive System Neoplasm",
        "Refractory Malignant Male Reproductive System Neoplasm",
        "Refractory Malignant Mesothelioma",
        "Refractory Malignant Neoplasm of Multiple Primary Sites",
        "Refractory Malignant Oral Neoplasm",
        "Refractory Malignant Pharyngeal Neoplasm",
        "Refractory Malignant Skin Neoplasm",
        "Refractory Malignant Soft Tissue Neoplasm",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Malignant Thyroid Gland Neoplasm",
        "Refractory Malignant Urinary System Neoplasm"
      ],
      "interventions": [
        {
          "name": "Cord Blood-derived Expanded Allogeneic Natural Killer Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Months to 40 Years"
      },
      "enrollment_count": 12,
      "start_date": "2018-08-31",
      "completion_date": "2026-02-26",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-07-22T03:00:22.851Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03420963"
    },
    {
      "nct_id": "NCT06605404",
      "title": "Pan-tumor MRD Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Muscle Invasive Bladder Urothelial Carcinoma",
        "Esophageal Cancer",
        "Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma",
        "Melanoma (Skin Cancer)",
        "NSCLC (Non-small Cell Lung Cancer)",
        "Pancreatic (Exocrine Only)",
        "Mix of Solid Tumors (MOST)"
      ],
      "interventions": [
        {
          "name": "blood and tissue samples",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "blood and tissue samples",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "Paradigm Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1350,
      "start_date": "2025-01-08",
      "completion_date": "2032-04",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-07-22T03:00:22.851Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Maumee, Ohio",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Maumee",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06605404"
    },
    {
      "nct_id": "NCT05600933",
      "title": "Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Solid Tumors",
        "Hematologic Malignancy",
        "Gastrointestinal Cancer",
        "Liver Cancer",
        "Pancreatic Cancer",
        "Melanoma",
        "Pre-Malignancy",
        "Lung Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1200,
      "start_date": "2023-05-15",
      "completion_date": "2033-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-07-22T03:00:22.851Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05600933"
    },
    {
      "nct_id": "NCT00072215",
      "title": "Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Extragonadal Germ Cell Tumor",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "vinblastine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 1,
      "start_date": "2004-04",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2016-07-04",
      "last_synced_at": "2026-07-22T03:00:22.851Z",
      "location_count": 78,
      "location_summary": "Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00072215"
    },
    {
      "nct_id": "NCT01955915",
      "title": "Blood Vessel Patterns in Small Choroidal Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Small Posterior Choroidal Tumors"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2013-10",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2022-10-12",
      "last_synced_at": "2026-07-22T03:00:22.851Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01955915"
    },
    {
      "nct_id": "NCT01113398",
      "title": "AMG 102 and Avastin for Recurrent Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "AMG 102",
          "type": "DRUG"
        },
        {
          "name": "Avastin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Katy Peters",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2010-08",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2015-12-10",
      "last_synced_at": "2026-07-22T03:00:22.851Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01113398"
    },
    {
      "nct_id": "NCT07025226",
      "title": "Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Fisetin",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Patient Observation",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Quercetin",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Topoisomerase-1 Inhibitor LMP744",
          "type": "DRUG"
        },
        {
          "name": "Single Agent Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-08-12",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-07-22T03:00:22.851Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07025226"
    },
    {
      "nct_id": "NCT00095836",
      "title": "Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Gefitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2003-03",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-05-31",
      "last_synced_at": "2026-07-22T03:00:22.851Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00095836"
    }
  ]
}